0001563355-14-000002.txt : 20141223 0001563355-14-000002.hdr.sgml : 20141223 20141223152644 ACCESSION NUMBER: 0001563355-14-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20141223 DATE AS OF CHANGE: 20141223 EFFECTIVENESS DATE: 20141223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hera Therapeutics Inc. CENTRAL INDEX KEY: 0001563355 IRS NUMBER: 800865383 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-230775 FILM NUMBER: 141306564 BUSINESS ADDRESS: STREET 1: 14024 RUE SAINT RAPHAEL CITY: DEL MAR STATE: CA ZIP: 92014 BUSINESS PHONE: 415 983 1000 MAIL ADDRESS: STREET 1: 14024 RUE SAINT RAPHAEL CITY: DEL MAR STATE: CA ZIP: 92014 D 1 primary_doc.xml X0707 D LIVE 0001563355 Hera Therapeutics Inc. c/o Janssen Laboratory Accelerator 3210 Merryfield Row San Diego CA CALIFORNIA 92121 858-342-5556 DELAWARE None None Corporation true 2012 Karl Y. Hostetler c/o Janssen Laboratory Accelerator 3210 Merryfield Row San Diego CA CALIFORNIA 92121 Executive Officer Director President and Chief Executive Officer Michael J. Sullivan c/o Pillsbury Winthrop Shaw Pittman LLP Four Embarcadero Center, 22nd Floor San Francisco CA CALIFORNIA 94111 Executive Officer Secretary William L. Respess c/o Janssen Laboratory Accelerator 3210 Merryfield Row San Diego CA CALIFORNIA 92121 Director Michael D. Cannon c/o Janssen Laboratory Accelerator 3210 Merryfield Row San Diego CA CALIFORNIA 92121 Director John W. Sayward c/o Janssen Laboratory Accelerator 3210 Merryfield Row San Diego CA CALIFORNIA 92121 Executive Officer Chief Operating Officer, Chief Financial Officer and Treasurer Biotechnology Decline to Disclose 06b false 2014-12-08 false true false 1 2545018 1745019 799999 This filing covers the purchase and sale of Series B Preferred Stock, which includes the conversion of convertible promissory notes. false 19 0 0 0 false Hera Therapeutics Inc. /s/ John W. Sayward John W. Sayward Chief Financial Officer 2014-12-22